Previous published work has indicated that treatment of the inside of the nose with certain wavelengths of light can reduce the symptoms of allergic rhinitis. The objective of the study was to compare the efficacy of the phototherapy device on the relief of a range of symptoms provoked by indoor and outdoor allergens. A phototherapy emits visible light (mUV/VIS) and infra red light and was compared to a placebo device which did not emit light on a two groups of allergic rhinitis sufferers. Rhinophototherapy improved nasal symptoms of allergic rhinitis arising from exposure to indoor and outdoor allergens. The difference in the intensity of symptoms scored at the baseline and at the final visit for the group using the photoperiod device was significantly lower.
Introduction
The nose is the first line of defence against inhaled potentially harmful airborne particles. By 2 acting as a filter it prevents allergens from reaching the bronchial tree. Allergic rhinitis (AR) 3 results from the inflammation of the nasal lining caused by an allergen such as pollens, moulds, 4 dust or certain animal danders which cause symptoms such as nasal irritation, sneezing, 5 rhinorrhoea and nasal blockage 1 . These common reactions affect approximately 25% of the 6 7 population worldwide and can lead to a reduction in the quality of life with economic impacts 2.3 . 8 9 AR is often treated using pharmacological products such as antihistamines, corticosteroids or 10 cromolyns either on their own or in a combination depending on the symptoms experienced. 11 12 However, there are sufferers who do not wish to take medication or for whom medication is contraindicated 4 . There are also allergic rhinitis sufferers who wish to reduce the amount of 13 medication that they take, or who find that medication is not sufficient to control their 14 symptoms. One possible method in reducing the dosages of pharmacological products may be 15 to combine their usage with other methods. 16 17 Previous published work has indicated that treatment of the inside of the nose with certain 18 wavelengths of light can reduce the symptoms of allergic rhinitis 5 . Early studies looked at the 19 effects on perennial/persistent rhinitis and more recent studies 6.7 have looked at the effect on 20 seasonal/intermittent allergic rhinitis. Phototherapy has an immunosuppressive effect and is 21 widely used for the treatment of immune mediated skin diseases. Phototherapy devices are able to inhibit immediate type hypersensitivity reaction in the skin. 24 Intranasal phototherapy is an approach more suitable for treatment of allergic rhinitis. In two 25 26 open studies, 308 nm excimer laser and topical PUVA therapy efficiently inhibited clinical symptoms of allergic rhinitis 5 . In a randomized, double-blind study combined low dose UVB, 27 low dose UVA and visible light proved to be effective in reducing symptom scores for 28 sneezing, rhinorrhea, nasal itching and the total nasal score in ragweed allergic patients. Light The study reported here investigated the effect of a phototherapy on seasonal/intermittent and 39 perennial/persistent allergic rhinitis symptoms with sufferers who may be affected by one or 40 more allergen sources. The nose probe covers are removed and the On/Off button depressed for 1 second, to activate 51 the two wavelengths (Figure1). The two nasal probes are inserted into the nasal cavity by 52 pressing the 2 adjustment buttons. The treatment lasts for 3 minutes and the device 53 automatically turns off once the treatment is completed. The device was used by participants 54 for 3 minutes, twice a day, 5 to 6 hours apart. A placebo device which did not emit light was 55 used on the control group. Participants used the active and placebo device in the morning and 56 evening, although participants were able to fit the use into their normal daily schedules. The 57 study was designed so that participants used the device for 3 weeks with readings taken after 2 58 weeks (mid study visit-MSV) of use and again after three weeks of use (final study visit -FSV). Data and other sample size calculations from previous studies were used to determine the sample size required for this study 9.10 . The study comprised of 52 participants with sensitivity 63 to grass and 50 participants with either sensitivity to cat and/or house dust mite. Participants 64 were provided with a participant information sheet on the nature and scope of the study and 65 were required to submit a signed informed consent form. Inclusions and exclusions were 66 applied. Participants had to be aged 18 years of age or older and sensitive to grass pollen and/or 67 cat dander and/or house dust mite allergen within the previous 2 years. Participants with a 68 history of asthma, nasal deformities/polyposis and sensitive skin were excluded. They were 69 also excluded if they had reported medical conditions or had cold, flu or rhinitis during the 70 initial visit. Potential participants were skin prick tested for their sensitivity to grass pollen, cat dander and 75 house dust mite allergen using standard solutions (ALK 7 Abello Soluprick SQ allergen extract Participants reported their allergic rhinitis symptom history using scoring scales to ensure they were suitable to participate in the trial ( Table 1) (cat dander and/or house dust mite allergen) only. This showed that there were 52 people with 89 allergy to grass pollen, and 50 people with allergy to cat dander and/or house dust mites (Table   90 2). Details of the gender and age breakdown of participants is also shown on Table 2 . At the 91 start of the trial no participant was showing any symptoms associated with allergic rhinitis. 
Method of Allergen Exposure

110
A controlled environment test chamber was used in the studies during exposure to allergens.
111
The chamber was set to a typical summer's day with an ambient temperature of 20 o C with a 112 humidity of 50%. A self-contained allergen challenge chamber which was used to replicate 113 different conditions was located within the environmental test chamber. Previous studies have 114 established allergen challenge chambers as being suitable for studies using allergens 15.16.17 . Table 3 . Mann Whitney-U test was used to determine significance (p=≤ 0.05). All statistical tests were 152 carried out two-tailed at 5% significance levels. 156 No serious adverse effects were reported either during or after the study from the participants 157 using the protocol applied. Two participants reported that they had severe rhinorrhoea while 158 using their devices, however both of these participants were in the placebo group. One (Table 4a) . (Table 4b) , with an overall mean of 7 (SD=2). The total TNSS for the treatment group at the 174 first visit at the beginning of the trial was 220, with an overall mean of 7 (SD=2). There was 175 no significant difference in the TNSS for the treatment group and the placebo group at the first 176 visit at the beginning of the trial (p= 0.25014). There was no significant difference in the TNSS 177 for the treatment group and the placebo group at the first visit at the beginning of the trial for 178 the different categories of allergen (Table 4b ). The total TNSS for the placebo group at the 179 final visit was 209, with an overall mean of 7 (SD=2). The total TNSS for the treatment group 180 at the final visit was 142 (Table 4b) , with an overall mean of 4 (SD=2). The TNSS showed that there was little change in the intensity of symptoms scored at the 184 baseline and at the final study visit for participants in the placebo group (p=0.09492); with only 185 a slight change in numbers at each intensity level. The difference in the intensity of all 186 symptoms scored at the baseline and at the final visit for the group using the photoperiod device 187 was significantly lower (p=0.00024***) (Table 4b ) with a reduction in the intensity of 188 symptoms ( Table 5 ). The effect of the photoperiod device was observed mainly in the total The outcomes for the different sensitivity groups followed a similar pattern to the overall study (Table 6a and 6b). There was a consistent decrease in the TNSS scores from the baseline visit 196 to the final visit across the three allergen groups (Table 6a) . This was not observed in the 197 placebo group where the TNSS scores either remained the same or changed by only one score.
Results
155
Effect of phototherapy on Eye and Nose allergic reactions
198
In the analysis of the treatments only the grass and cat/house dust mite allergen group showed 199 a difference that is statistically different (0.0093**) (Table 6b) between the placebo and treatment group at baseline visit were p= 0.6030 and p = 0.6241 203 respectively (Table 6b) .
205
Other allergic responses 206 Analysis of the scores for itchy throat and itchy mouth showed that there was no significant 207 difference between the treatment and placebo groups at the baseline visit for either of these two 208 symptoms. At the final visit symptoms of itchy throat (p=0.105) and itchy mouth (p=0. 20408) 209 were not significantly reduced by phototherapy ( Table 7) . Analysis of the scores for coughing 210 showed that there was no significant difference between the treatment and placebo groups at 211 the baseline visit (p=0.2301). At the final visit there was a reduction in the total coughing scores 212 for the treatment group which was found to be statistically significant (p=0.00341**). Allergic rhinitis is the most frequent atopic response which affects potentially 25%-35% of the 216 adult population and this shows an upward trend 20.21.22 . Previous studies reported using 217 controlled conditions showed that persistent allergic rhinitis patients benefited from adding 218 phototherapy to the medical treatment, using combined UVA, UVB, and visible lights 219 (mUV/vis) 23 . In these studies nasal obstruction, sneezing, rhinorea, and nasal itching showed histamines are traditionally prescribed as over the counter medical therapies but there many 230 sufferers who do not wish to take medication or for who medication is contraindicated. There 231 are also allergic rhinitis sufferers who wish to reduce the amount of medication that they take, 232 or who find that medication is not sufficient to control their symptoms. In other reported moderate or mild at the end of the study. All participants in the treatment group had some 245 reduction in one or more of their nasal symptoms.
247
The phototherapy device was not shown to be effective for the ocular symptoms but the effect 248 was statistically significant for coughing. There is an indication that the reduction of nasal 249 symptoms can have a secondary effect of helping to alleviate the symptoms of itchy throat and 250 the need for coughing by reducing excessive mucus production.
252
This study demonstrates that phototherapy may be an effective method for treating and 253 reducing the effects of symptoms for sufferers of allergic rhinitis particularly those affecting 254 the nose. The device could be used in place of other treatments for some sufferers or as an 255 256 additional treatment for those who find that traditional medication is not sufficient to control their symptoms or when allergen levels are particularly high 25 . In this study phototherapy was 257 shown to be effective in reducing symptoms attributed to several allergens alone or in 258 combination. This makes it particularly useful in the treatment of allergic rhinitis. Table 1 Criteria for assessing allergy history of participants 
